Enzene Biosciences
PrivateLast Round
Series B
Feb 13, 2026
Total Funding Raised
$36.3M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Enzene Biosciences operates in Healthcare & Life Sciences and is based in Pune. Its latest recorded funding round was a Series B round in February 2026.
Enzene Biosciences is a biotechnology company that provides end-to-end contract development and manufacturing organization (CDMO) services and develops biosimilar products using its proprietary continuous manufacturing platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clean Manufacturing, Drug Discovery, Quality Management
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enzene Biosciences Comparables
Compare Enzene Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rentschler Biopharma SE | 84% | |
| Polpharma Biologics | 83% | |
| Evotec | 80% |
For institutional investors. Book with your work email.
Enzene Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 13, 2026 | ||||
| Corporate Funding | Dec 26, 2025 | ||||
| VC Round | Jan 30, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Enzene Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| F-Prime Capital | VC Round |
| Eight Roads Ventures | VC Round |
| F-Prime Capital | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 14, 2026
Now a subsidiary of Alkem Laboratories.
- Mar 1, 2026
Operational alignment suggests a close relationship with the Alkem group.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withOct 27, 2026
The partnership covers Enzene Biosciences Ltd.'s development and manufacturing support for Adalvo's romiplostim program, including international regulatory filings and product supply from India.
For institutional investors. Book with your work email.
Enzene Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Enzene Biosciences's valuation, stock price, and market status.
Is Enzene Biosciences a public or private company?
Enzene Biosciences is a private company.
What is the current stock price of Enzene Biosciences?
Enzene Biosciences is a private company, so its shares have no public market price. Caplight tracks Enzene Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Enzene Biosciences worth (valuation)?
Valuation information for Enzene Biosciences is not publicly available.
Can I buy Enzene Biosciences stock?
Enzene Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Enzene Biosciences's last funding round?
Enzene Biosciences's most recent funding round was Series B on February 13, 2026.
Who are the main investors in Enzene Biosciences?
Key investors in Enzene Biosciences include F-Prime Capital, Eight Roads Ventures, F-Prime Capital.
Will Enzene Biosciences IPO soon?
No public IPO plans have been announced for Enzene Biosciences.
How can I track Enzene Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Enzene Biosciences's shares on secondary markets.